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The global control of tuberculosis (TB) is at risk by the spread of multidrug-resistant TB (MDR TB). Treatment of MDR TB is
lengthy and involves injected drugs, such as capreomycin, that have severe side effects. It was previously reported that a single
daily dose of inhaled capreomycin had a positive effect on the bacterial burden of TB-infected guinea pigs. The modest effect
observed was possibly due to a dose that resulted in insufficient time of exposure to therapeutic systemic and local levels of the
drug. In order to determine the length of time that systemic and local drug concentrations are above therapeutic levels during
the treatment period, the present study investigated the disposition of capreomycin powders after sequential pulmonary admin-
istration of doses of 20 mg/kg of body weight. Capreomycin concentrations in bronchoalveolar lavage fluid and lung tissue of
animals receiving a series of one, two, or three doses of capreomycin inhalable powder were significantly higher (50- to 100-fold)
at all time points than plasma concentrations at the same time points or those observed in animals receiving capreomycin solu-
tion by intramuscular (i.m.) injection (10- to 100-fold higher). Notably, at the end of each dosing period, capreomycin concen-
trations in the lungs were approximately 100-fold higher than those in plasma and severalfold higher than the MIC, suggesting
that sufficient capreomycin remains in the lung environment to kill Mycobacterium tuberculosis. No accumulation of capreomy-
cin powder was detected in the lungs after 3 pulmonary doses. These results indicate that the systemic disposition of capreomy-
cin after inhalation is the same as when injected i.m. with the advantage that higher drug concentrations are present at all times
in the lungs, the primary site of infection.
Multidrug-resistant tuberculosis (MDR TB) is an increasingchallenge for the treatment and control programs of TB, a
global deadly disease. Inappropriate treatment regimens with
“first-line” drugs (mainly isoniazid and rifampin) and poor pa-
tient adherence to treatment have led to the increase in the num-
ber of MDR TB cases and, lately, the emergence of extensively
drug-resistant cases (XDR TB) (8). Current international guide-
lines for the treatment of MDR TB recommend a treatment course
of at least 18 months of “second-line” agents, including at least
one of the following: capreomycin, ethionamide, kanamycin, or
amikacin (22). With the exception of ethionamide, all these are
administered by injection. These agents are more toxic, than gen-
erally not well tolerated, and less effective than first-line agents
(19). While MDR TB is difficult to cure, XDR TB is often fatal;
therefore, the judicious use of second-line drugs must be ensured
to cure MDR TB or decrease its transmission and prevent emer-
gence of XDR TB. Despite new drugs being evaluated, the present
situation requires action to improve existing drug efficacy, deliv-
ery strategies, and mechanisms that support patient adherence to
the prescribed treatment (11).
The major limiting factor for the use of capreomycin in the
treatment of MDR TB is its severe systemic side effects. These
include anorexia, thirst, anemia, hearing loss, and, notably, neph-
rotoxicity (proteinuria, hematuria, nitrogen metabolism, and
electrolyte disturbances) (3, 7, 18). It was previously postulated
that formulation of capreomycin into solid particles for inhalation
would increase drug concentrations at the site of infection, the
lungs, while decreasing systemic toxicity, thus rendering a more
effective approach for the treatment of pulmonary TB. Previous
studies by our group reported the disposition of a single dose of
capreomycin solution administered by the intravenous (i.v.) and
intramuscular (i.m.) routes and of solid particles delivered by the
pulmonary route in guinea pigs (5). Pharmacokinetic (PK) pa-
rameters after administration of capreomycin solutions or sus-
pensions have been determined in only mice and humans (2, 3, 7,
9, 14–16, 20), and there are no reports of these studies in guinea
pigs, a species known to have drug disposition characteristics that
are different from those of other rodents. Our study showed that
capreomycin plasma concentrations were comparable in animals
receiving capreomycin by the systemic and pulmonary routes af-
ter 2 h of drug administration (5). PK parameters indicated that
capreomycin was eliminated at a lower rate when delivered by the
pulmonary route than when delivered i.v. and i.m., resulting in a
significantly longer half-life. Subsequent studies evaluated the ef-
fect of daily doses of these capreomycin formulations on the ex-
tent of infection in the guinea pig model of TB (5). Animals re-
ceiving capreomycin dry powder aerosols showed a significantly
smaller degree of inflammation, bacterial burden (CFU/ml), and
percentage of lung tissue affected by granulomas and caseous ne-
crosis (by histopathology) compared to those with the conven-
tional treatment. However, in this efficacy study, the doses of
capreomycin were delivered as an aerosol by passive, nose-only
exposure to awake animals as required for a 1-month daily dosing
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regimen. Since guinea pigs are obligate nose breathers, this
method of aerosol delivery resulted in a fraction (2 mg/kg of body
weight) of the nominal dose (14.5 mg/kg) reaching the periphery
of the lungs, unlike the anticipated situation in humans in which
inhalation through the mouth would result in a larger proportion
of the dose reaching the periphery of the lungs. A PK study design
in which particles were insufflated by the endotracheal tube in
sequential dosing more accurately reflects human dosing and was
considered a prerequisite for understanding dosing in the phase
IA clinical studies in healthy volunteers.
The present study was designed to build upon the findings
described above to evaluate the effect of directly administering
sequential known doses of capreomycin powders by the pulmo-
nary route on local and systemic levels of the drug. The goal of this
study was to determine the disposition of sequential doses of in-
haled capreomycin and the ability to sustain local and systemic
therapeutic levels for TB treatment. PK parameters were deter-
mined to characterize the disposition of sequential doses of
capreomycin powder for inhalation. Capreomycin plasma levels,
peak concentration, and time to achieve that concentration will
aid in the calculation of a possible dose size to attain appropriate
therapeutic levels of the drug, whereas mean residence time, half-
life, and clearance will dictate the dosing regimen required to
maintain therapeutic drug levels.
MATERIALS AND METHODS
Materials. Capreomycin sulfate powder drug product (98% purity; Zhe-
jiang Hisun Pharmaceutical Co., China) was employed to prepare the
solution for injection. Capreomycin powder for inhalation (batch
MS08MED035 BR7) was manufactured by Micro-Sphere SA (Madonna
del Piano, Switzerland) by procedures described previously (4, 5) and
used as supplied. Capreomycin powder for inhalation was characterized
in terms of drug content, volume, aerodynamic diameters, and fine par-
ticle fractions (FPF). Capreomycin content in the powder for inhalation
was 80%, as determined by high-performance liquid chromatography
(HPLC).
Powders had a volume diameter of 2.71 m and a geometric standard
deviation (GSD) of 1.74, as determined by the HELOS system with a
RODOS dry dispersing unit (Sympatec Inc., Lawrenceville, NJ). Analysis
of the powders by cascade impaction (Andersen eight-stage Mark II cas-
cade impactor; Thermo-Electron, Waltham, MA) indicated that the pow-
ders had appropriate aerodynamic properties for inhalation, with a mass
median aerodynamic diameter (MMAD) of 3.7 m and fine particle frac-
tions for FPFTD values of 5.8 m and 3.3 m of 74.6% and 31.5%,
respectively, where TD is total dose.
Animals. Male guinea pigs (n  86) weighing an average of 598.5 
74.0 g were employed in these studies. The animals were housed in a 12-h
light/12-h dark cycle and a constant temperature environment of 22°C. A
standard diet and water were supplied ad libitum. All animal procedures
were approved by the Institutional Animal Care and Use Committee of
the University of North Carolina.
Twenty-four hours before the study, each animal underwent cannu-
lation of the right external jugular vein for continuous blood sampling.
The cannula was routed subcutaneously, externalized at the neck, and
secured to musculature.
Treatments. The animals were randomly divided into three groups,
with each receiving a different number of pulmonary doses (20 mg/kg per
dose) of capreomycin powder per day as outlined in Table 1. Animals
receiving a single dose of capreomycin solution by the i.m. route were
employed as controls. The dose employed in this study was selected based
on previous studies performed in our laboratory (5). Capreomycin solu-
tions were prepared by dissolving a weighed amount of capreomycin sul-
fate powder drug in water for injection and filtering the solution through
a 0.22-m Millex GS filter (Millipore, Cork, Ireland). Capreomycin pow-
ders for inhalation were preweighed in a gelatin capsule (V-Caps; Capsu-
gel, Greenwood, SC) and administered to the animals by insufflation. For
this procedure, each animal was anesthetized and the trachea was visual-
ized with a laryngoscope. A small-animal insufflator (Penn Century Inc.,
Philadelphia, PA) was inserted into the trachea and placed at a distance of
1 cm from the carina. Capreomycin powders were aerosolized from the
reservoir of the insufflator into the animal’s airways with the help of 5 ml
of air from an empty syringe. The insufflator chamber and the tube con-
taining the capreomycin powder were weighed carefully before and after
delivery to the animal to verify that the entire dose was delivered.
Blood samples (0.25 ml) were collected from each animal into hepa-
rinized microcentrifuge tubes at 0, 0.08, 0.25, 0.50, 1, 1.5, 2, 3, 4, 5, 6, and
8 h after administration of capreomycin powder or solutions. Sterile saline
solution was used to replace the volume of blood drawn at each sample
collection. Samples were then centrifuged, and plasma was separated and
stored at 80°C until analysis. For animals receiving a single dose, lung
tissues were collected and a bronchoalveolar lavage (BAL) was performed
at 0.5, 2, 4, and 8 h to determine capreomycin local concentrations in
tissue and airways. Since BAL is a terminal procedure for guinea pigs,
extra animals were employed for each time point as indicated in Table 1.
For animals receiving two or three doses, lung tissue and BAL fluid were
collected at 0.5 and 8 h after each dose as shown in Table 1. After collection
of the last blood sample, animals were euthanized by exsanguination and
BAL was performed by instilling 5 ml of sterile saline as described before
(6). Tissues were visually inspected for any signs of toxicity. Lungs and
tracheae were resected and frozen immediately at 80°C until analysis.
Sample analysis. Capreomycin was extracted from plasma samples by
acid extraction using perchloric acid solution followed by vortex mixing
and centrifugation. The acid was then neutralized with a basic mix of 1:10
KOH/K2HPO4 solution. Supernatant was transferred to glass injection
vials for HPLC analysis. A standard curve was constructed by spiking
known concentrations of capreomycin (0.5 to 35 g/ml) into blank
plasma and treating them as described before (5). To determine capreo-
mycin levels in lung tissue, the right lower lobe for each animal was
weighed and homogenized in phosphate buffer, pH 6, and capreomycin
was extracted from the homogenate as described for plasma samples. A
standard curve was constructed by spiking known concentrations of
capreomycin (0.5 to 35 g/ml) into blank lung homogenates and treating
them in the same manner as the plasma samples. Capreomycin in BAL
fluid was determined by first sonicating BAL fluid samples to disrupt cell





dosesa/day Dosing time(s) (h) Time(s) of BAL (h)
No. of guinea pigs per respective
BAL time point (total no. of
guinea pigs per group)
1 Powder (pulmonary) One 0 0.5, 2, 4, 8 8, 8, 9, 7 (32)
2 Powder (pulmonary) Two 0, 8 8.5, 16 6, 8 (14)
3 Powder (pulmonary) Three 0, 8, 16 16.5, 24 8, 8 (16)
4 Solution (i.m.) One 0 0.5, 2, 4, 8 6, 6, 6, 6 (24)
a 20 mg/kg each.
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contents and then vortex mixing and centrifuging them. The supernatant
was analyzed by HPLC for drug content.
Capreomycin concentrations in plasma, BAL fluid, and tissues were
determined by HPLC as follows. The system (Waters Corp., Milford, MA)
consisted of a model 510 pump, a model 717 plus autosampler, and a
model 480 UV detector set at a wavelength of 268 nm. The system was
equipped with a Nova-Pak C18 guard column and a Waters Spherisorb
ODS2 analytical column (5-m particle size; 4.6-mm diameter; 150-mm
length). The mobile phase consisted of 92% phosphate buffer, pH 6, 8%
acetonitrile, and 0.3% heptafluorobutyric acid. The limit of capreomycin
detection by this assay in all samples was 0.05 g/ml. The concentration
reported in BAL fluid was calculated taking into account the volume of
epithelial lining fluid in guinea pigs (10) and the volume of saline solution
used to perform the lavage.
Data analysis. (i) Pharmacokinetic analysis. Capreomycin plasma
concentration-versus-time data were analyzed by noncompartmental
methods (WinNonlin; Pharsight Corporation, Mountain View, CA) to
obtain the area under the curve (AUC), the apparent total body clearance
(CL), the mean residence time (MRT), the half-life (t1/2), and the elimi-
nation rate constant (kel). The maximum capreomycin concentration
(Cmax) and time to obtain the maximum capreomycin concentration
(Tmax) were determined directly from the plasma-versus-time profiles for
each individual animal. Relative bioavailability (F=) was calculated using
the area under the curve from 0 h to t (AUC0-t) values with the i.m.
administration as a reference.
(ii) Statistical analysis. Data from plasma, BAL fluid, lung tissue, and
PK parameters were subjected to analysis of variance (ANOVA) and the
least-squares significant-differences multiple-comparison method. A
probability level of 5% (P  0.05) was considered to be statistically signif-
icant.
RESULTS
Capreomycin plasma concentration-versus-time curves are
shown in Fig. 1. Similar capreomycin plasma concentrations were
observed for all animals after receiving capreomycin powders by
the pulmonary route. Compared to i.m. injection, capreomycin
was absorbed faster when administered by the pulmonary route,
as evidenced by the significantly higher (P  0.0003) plasma con-
centrations at initial time points (0.08 and 0.25 h) (Fig. 1). At later
time points (0.5, 1.0, and 2 h), plasma concentrations were signif-
icantly higher (P  0.005) in animals dosed by the i.m. route, but
from the 2-h time point onward, plasma concentrations were sim-
ilar (P  0.5) for both i.m. and pulmonary routes of administra-
tion. These parallel terminal phases indicated the same first-order
elimination mechanism for both routes of administration.
BAL was performed in all animals at different time points, as
indicated in Table 1, and lung tissue was collected to determine
local capreomycin concentrations. As expected in animals dosed
by i.m. injection, capreomycin concentrations were higher in
plasma than in BAL fluid or lung tissue at all time points (Fig. 1
and Table 2). In these animals, BAL fluid and lung capreomycin
concentrations (Table 2) were highest (P  0.0001) at the 0.5-h
time point and decreased gradually, falling under detection limits
in most animals 8 h after receiving their dose. A similar concen-
tration-time trend was observed in animals dosed with capreomy-
cin powder by the pulmonary route, with maximum drug concen-
trations in BAL fluid and lung tissue observed at the 0.5-h time
point (Table 2) and decreasing gradually until 8 h. However, un-
like those in the i.m. group, capreomycin concentrations re-
mained more than 15-fold above the detection limit in BAL fluid
and more than 100-fold above the detection limit in lung tissue
(Table 2) in animals dosed by the pulmonary route. Moreover,
while local drug concentrations were of magnitudes similar to
those in plasma at all time points for i.m.-dosed animals, capreo-
mycin concentrations were significantly higher in BAL fluid (5- to
10-fold; P  0.0001) and lung tissue (10- to 100-fold; P  0.0001)
than in plasma (Table 2 and Fig. 1) at all time points for animals
dosed by the pulmonary route.
Furthermore, when comparing concentrations at each time
point for both routes of administration, capreomycin concentra-
tions in the BAL fluid of animals dosed by the pulmonary route
were 70- to 170-fold higher (P  0.0001) than those observed in
i.m.-dosed animals (Table 2). Likewise, capreomycin lung tissue
concentrations were 10- to 63-fold higher (P  0.0001) in animals
dosed by the pulmonary route than in those receiving i.m. injec-
tion (Table 2).
FIG 1 Average-plasma-concentration-versus-time curves after administra-
tion of capreomycin solution or powder for inhalation for the following dif-
ferent dosing regimens (average  standard deviation, n  8 to 14): one dose
of capreomycin powder for inhalation by insufflation (Single-Insuff), two
doses of capreomycin powder for inhalation by insufflation (Double-Insuff),
three doses of capreomycin powder for inhalation by insufflation (Triple-
Insuff), and one dose of capreomycin solution by intramuscular administra-
tion (Single-IM). Asterisks indicate significant differences in concentration at
that time point.
TABLE 2 Average capreomycin concentrations in BAL fluid and lung
tissue of animals receiving a single dose of capreomycin by
intramuscular injection or pulmonary administration at different time
points after dose administration
Route of administration





0.5 2.9  1.1 16.9  5.4
2 0.4  0.0 14.9  3.7
4 0.6  0.3 11.2  2.8
8 0.1  0.1 1.9  2.0
Pulmonary
0.5 264.6  82.2* 475.2  243.64*
2 83.1  72.2* 194.9  51.1*
4 7.1  3.4* 77.4  23.1*
8 7.2  6.6* 106.8  28.9*
a Average  standard deviation. n  6 to 9. *, significantly higher than i.m.
concentration at that time point.
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The capreomycin concentration trends observed in plasma,
BAL fluid, and lung tissue of animals dosed by the pulmonary
route (Fig. 1 and Table 2) indicate that capreomycin absorp-
tion was limited by dissolution of the powder in the airways.
The higher initial concentrations in lung tissue (Table 2) and in
plasma (Fig. 1) indicated that after dissolution, absorption into
lung tissue and plasma occurred very quickly. However, the
advantage of pulmonary administration of capreomycin is that
lung tissue concentrations remained above the MIC even after
plasma levels were at or below detection limits (8 h) (Fig. 1 and
Table 2).
Table 3 shows BAL fluid and lung tissue concentrations at the
maximum and minimum plasma concentrations (Cmax at 0.5 h
and Cmin at 8 h after administration of each dose). At the time of
Cmax, animals receiving a single dose of capreomycin powder by
the pulmonary route exhibited BAL fluid concentrations that were
significantly higher (264.6 g/ml; P  0.0001) than those ob-
served in the i.m. group (2.9 g/ml) (Table 3). It is important to
note that in animals dosed by the pulmonary route, BAL fluid
concentrations were significantly higher (3- to 6-fold; P  0.0001)
than those observed in plasma at that time point (Fig. 1 and Table
3). Lung tissue concentrations were also the highest (P  0.0001)
after pulmonary administration of a single dose of capreomycin,
and they were similar (P  0.0001) for two and three administered
doses of powder (Table 3). Notably, lung tissue concentrations
were 200- to 300-fold higher in animals dosed by the pulmonary
route than in those in the i.m. group. Capreomycin concentra-
tions were also approximately 2-fold higher in lung tissue than in
BAL fluid (Table 3) and 4- to 10-fold higher in lung tissue (P 
0.0001) than in plasma at those time points (0.5, 8.5, and 16.5 h)
(Fig. 1 and Table 3).
Capreomycin concentrations in BAL fluid and lung tissue were
also determined at the end of the dosing period for each regimen
(time of Cmin  8, 16, or 24 h) to compare local drug concentra-
tions with systemic concentrations at the same time points (Fig. 1
and Table 3). Consistent with other time points, BAL fluid con-
centrations in animals dosed by the pulmonary route at the time
of Cmin were 35- to 105-fold higher (P  0.0001) than those in
i.m.-dosed animals. Remarkably, these BAL fluid concentrations
in animals dosed by the pulmonary route were 2- to 3-fold higher
(P  0.003) than the MIC (MIC  2.5 g/ml) for capreomycin
and, consequently, the drug was still available to act on bacteria in
the airways, whereas plasma concentrations were below MIC lev-
els at this time point (Fig. 1 and Table 3), highlighting the advan-
tage of administering drugs by the pulmonary route.
Likewise, lung tissue concentrations in animals dosed by the
pulmonary route were 60- to 80-fold higher (P  0.0001) at the
time of Cmin than those in i.m.-dosed animals and approximately
100-fold higher than plasma concentrations (P  0.0001) at that
time point. Most importantly, capreomycin levels in lung tissue
were 40- to 50-fold times higher than the MIC (P  0.0001), a
result which suggests that some drug remained present in the lung
to kill bacteria at the site of colonization even after systemic levels
fell below the MIC.
Table 3 also shows that capreomycin levels in lung tissue were
comparable (P  0.2, no statistical difference) in animals receiv-
ing one, two, and three doses of capreomycin powder in a day,
indicating that there is no drug accumulation in the lungs which
may have had undesired effects on lung function.
PK parameters obtained by noncompartmental methods for
capreomycin disposition are presented in Table 4. A comparison
of the single/first doses among all treatments (lines 1 to 9) indi-
cates that the AUCs and Cmax (lines 1, 2, and 7) were significantly
larger for i.m.-dosed animals than for animals dosed by the pul-
monary route (P  0.0001) and similar among animals dosed by
the pulmonary route. Clearance (CL; line 3) was significantly
smaller (P  0.0008) and the Tmax (line 8) was significantly longer
(P  0.0001) in i.m.-dosed animals than in animals dosed by the
pulmonary route, indicating that capreomycin may be absorbed
faster into systemic circulation from the lungs than from muscle.
No significant differences (P  0.1112) were observed in bioavail-
ability (F=) following the first dose among groups receiving
capreomycin by the pulmonary route.
A comparison of PK parameters in animals receiving more
than one dose per day indicated that in animals receiving two
sequential doses in a day, there were no significant differences in
PK parameters between the first and second doses (lines 1 to 18).
However, significant differences were observed in PK parame-
ters among doses in animals receiving three sequential doses. The
AUCs and Cmax (lines 19, 20, and 25) were significantly larger for
the third dose than for the other two doses (P  0.0027 and P 
0.0002, respectively), possibly due to a small quantity of capreo-
mycin still remaining in systemic circulation from the previous
two doses in two animals of that group. CL and the MRT (lines 21
and 24) were significantly smaller (P  0.005 and P  0.017,
respectively) after the first dose, an outcome which is reflected in a
significantly higher bioavailability (line 27; P  0.002) and corre-
lates well with higher concentrations in BAL fluid and lung tissue
for this group at the end of the dosing period. Interestingly,
capreomycin bioavailability after the third dose of aerosolized
powder was higher (P  0.0025) than that after any other dosing
regimen.
TABLE 3 Average capreomycin concentrations in BAL fluid and lung
tissue of animals receiving different numbers of sequential doses of
capreomycin by intramuscular injection or pulmonary administration
at the times of Cmax and Cmin
Route of administration
(dose no. within 1 day)





0.5 2.9  1.1 16.9  5.4
8 0.1  0.1 1.9  2.0
Pulmonary (one)
0.5 264.6  82.2** 475.2  243.64**
8 7.2  6.6** 106.8  28.9*
Pulmonary (two)
8.5 105.9  51.3* 294.4  129.3*
16 2.5  1.2* 100.8  37.4*
Pulmonary (three)
16.5 153.4  50.4* 275.5  61.1*
24 4.6  1.9* 102.4  36.8*
a Average  standard deviation. n  6 to 8.*, significantly different from i.m.
concentration at same time point; **, significantly different from i.m. concentration
and concentrations after two doses and three doses at same time point.
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DISCUSSION
Capreomycin, an existing second-line antibiotic for the treatment
of TB, has received renewed interest because it is effective against
MDR TB. There are few drugs active against nonreplicating bac-
teria, and capreomycin is the only one that has potential against
bacilli persistent in human tissues (12). However, its use has been
limited due to the associated toxicities to the auditory and visual
nerves as well as to renal toxicity (3, 7, 17, 18). Furthermore, it has
been reported that capreomycin absorption after i.m. injection
can be incomplete or delayed when the same site of injection is
used repeatedly (1).
Previous studies conducted by our group administering a daily
single dose of inhaled capreomycin powder to TB-infected guinea
pigs showed a significant decrease in the lung bacterial burden
compared to that of the conventional parenteral treatment (5).
Histopathological analysis showed a positive effect of the inhaled
treatment on the lungs and spleen. This treatment also resulted in
a significant decrease in the bacterial burden in the lungs, but not
the spleen, of infected animals, possibly due to systemic drug levels
that were transiently above the MIC (5). Therefore, this study
determined the disposition of sequential doses of inhaled capreo-
mycin and the ability of pulmonary administration to sustain local
and systemic therapeutic levels for TB treatment and addressed
the concern of powder accumulation in the lungs, which may be
detrimental for the patient.
The disposition of each capreomycin powder dose was assessed
and characterized by the respective PK parameters. In the present
study, capreomycin powders with particle sizes, drug content, and
aerodynamic properties similar to those used in the previous
study (5) were employed. Yet the disposition of capreomycin that
was determined in previous studies (employing capreomycin
from Eli Lilly and Co.), was different from the disposition of
capreomycin in the present studies (employing capreomycin from
Zhejian Hisun Pharmaceutical Co.) for single-dose/first-dose an-







Single dose Double dose Triple dose
First dose
1 AUC0-t (g · h/ml) 104.16  25.56
1 75.54  16.202 74.42  11.982 64.92  11.422
2 AUC0- (g · h/ml) 116.29  47.63
1 79.04  15.812 76.55  12.832 67.27  11.282
3 CL (ml/h · kg) 0.21  0.033 0.25  0.052 0.27  0.051,2 0.31  0.051
4 kel (h
1) 0.45  0.10 0.50  0.10 0.53  0.16 0.44  0.09
5 t1/2 (h) 1.51  0.39 1.45  0.33 1.39  0.34 1.62  0.32
6 MRT (h) 1.87  0.44 2.01  0.38 1.92  0.31 1.84  0.31
7 Cmax (g/ml) 38.47  4.20
1 30.16  7.142 31.38  4.812 26.98  5.262d
8 Tmax (h) 0.68  0.25
1 0.35  0.132 0.27  0.112 0.31  0.122
9 F= 0.73  0.16 0.71  0.11 0.62  0.11
Second dose
10 AUC0-t (g · h/ml) 74.97  14.78 78.09  16.64
11 AUC0- (g · h/ml) 77.23  15.25 80.74  17.24
12 CL (ml/h · kg) 0.27  0.06 0.27  0.07
13 kel (h
1) 0.51  0.19 0.46  0.06
14 t1/2 (h) 1.53  0.53 1.54  0.18
15 MRT (h) 1.68  0.53 1.67  0.20
16 Cmax (g/ml) 33.26  3.24 34.06  6.77
17 Tmax (h) 8.21  0.08 8.29  0.09
18 F= 0.72  0.14 0.75  0.16
Third dose
19 AUC0-t (g · h/ml) 92.69  18.90
c
20 AUC0- (g · h/ml) 103.66  24.34
c
21 CL (ml/h · kg) 0.22  0.06d
22 kel (h
1) 0.39  0.06
23 t1/2 (h) 1.80  0.31
24 MRT (h) 1.50  0.22d
25 Cmax (g/ml) 41.98  7.83
c
26 Tmax (h) 16.34  0.13
27 F= 0.89  0.18c
a AUC0-t, area under the curve from 0 h to t; AUC0-, area under the curve from 0 h to infinity; kel, elimination rate constant; t1/2, half-life; MRT, mean residence time; Cmax,
maximum concentration; Tmax, time at which Cmax occurs; F=, relative bioavailability compared to that of the i.m. injection.
b Mean  standard deviation. n  8 to 14. Each dose contained 20 mg/kg capreomycin. Numeric superscripts show the relative ranks of values. When the means are not
significantly different, the same superscript is used.
c Significantly larger for this dose than any other dose in this treatment.
d Significantly smaller for this dose than any other dose in this treatment.
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imals. In previous studies, capreomycin concentrations were un-
detectable in plasma 6 h after dose administration, whereas these
levels remain detectable 8 h after dosing in the present studies. In
previous studies, no capreomycin was detected in the BAL fluid of
animals dosed by the pulmonary route at the end of the dosing
period, whereas in the present study, capreomycin concentrations
in the BAL fluid at the end of the dosing period were well above
detection limits. The AUCs and Cmax were significantly higher,
clearance was faster, and the MRT was shorter for capreomycin in
the first study (5) than in the present study. Differences in these
parameters were reflected in the higher bioavailability of capreo-
mycin powders for inhalation that was observed in the present
study. These differences in capreomycin disposition may be at-
tributed to differences in the composition of the drug substance
(chemical entity). Capreomycin is isolated as 4 isomers from fer-
mentation broths (IA, IB, IIA, IIB), and drug substances primarily
contain isomers IA and IB. Based on the proportions of the areas
for each isomer analyzed by HPLC, we determined that there was
approximately 40% of IA and 60% of IB in the capreomycin drug
substance from Eli Lilly and Co., whereas there was approximately
65% of IA and 35% of IB in the capreomycin drug substance from
Zhejian Hisun Pharmaceutical Co. Even though it would be de-
sirable to study the disposition of each capreomycin isomer and its
influence on drug bioavailability, it is beyond the scope of the
present study.
Disposition of capreomycin in guinea pigs was different from
that observed in other species, as expected. In this study, the half-
life after i.m. injection of capreomycin to guinea pigs was 1.51 h,
whereas a half-life of 0.18 h is reported in mice (14) and it ranges
between 2 to 3 h (2) and 4 to 6 h (1) in humans. The Tmax after
capreomycin i.m. injection was 0.68 h in guinea pigs and 1 to 2 h in
humans, and capreomycin is also cleared (CL) faster in guinea pigs
(0.21 ml/h · kg) than in humans (0.011 ml/h · kg). Interestingly,
the Cmax after administration of a 20-mg/kg dose in guinea pigs
(38.47 g/ml) is comparable to that after administration of 1 g of
capreomycin in humans (20 to 47 g/ml) (13, 21).
Le Conte et al. (14) determined capreomycin concentrations in
tissues (lung, spleen, and kidney) at the same time point after i.v.
administration of free and liposomal capreomycin injections, but
to the best of our knowledge, the present study is the first in which
local (airways and lung tissue) and systemic concentrations were
evaluated and compared at different time points after sequential
pulmonary administrations of an antitubercular drug. Despite
differences in route of administration, formulations, dosing regi-
men, and animal species being employed, the comparison of re-
sults from the present study with those of Le Conte et al. empha-
sizes the advantage of delivering capreomycin by the pulmonary
route. In the study by Le Conte et al., at a Tmax of 0.25 h, the
capreomycin concentration in lung tissue was approximately half
that in serum after free drug administration and about twice that
in serum after liposomal administration of a 120-mg/kg dose by
the i.v. route (14). This concentration was also the highest con-
centration observed in lung tissue after administration of the dose.
In contrast, in the present study, at a Tmax of 0.5 h, capreomycin
concentrations were 7- to 10-fold higher in BAL fluid and 10- to
20-fold higher in lung tissue than in plasma following administra-
tion of a 20-mg/kg dose by the pulmonary route. Furthermore,
while serum levels fell below detection limits 2 h after free drug
administration and 4 h after liposomal i.v. administration of a
120-mg/kg dose in the study by Le Conte et al., capreomycin
plasma concentrations remained detectable up to 8 h after pulmo-
nary administration of 20 mg/kg capreomycin powder. Most im-
portantly, while capreomycin concentrations in lung tissue were
only 2- to 3-fold higher than the MIC for capreomycin 6 h after i.v.
administration, capreomycin concentrations remained 40- to 50-
fold higher than the MIC in lung tissue 8 h after pulmonary ad-
ministration of one-sixth of the dose in the present study, indicat-
ing that sufficient amounts of the drug are still present at the site of
delivery to kill bacteria. The dose size and number of administra-
tions did not cause any adverse events or drug accumulation in the
lungs of guinea pigs, and no histopathological changes were ob-
served as a result of powder administration.
The higher local concentrations achieved in the present study
and the similarity of the capreomycin disposition after pulmonary
administration to that after i.m. injection suggest that it may be
possible to obtain positive effects in TB treatment by using a
smaller dose of capreomycin administered by inhalation, thus re-
ducing the likelihood of systemic adverse effects. Beyond the effi-
cacy of an inhaled TB treatment with capreomycin, it may be
possible that pulmonary administration of capreomycin powders
would prevent transmission of MDR TB, since the number of
viable bacteria in the lungs of infected patients should be signifi-
cantly reduced by the inhaled treatment. Additional experiments
may be required to address the disposition of the drug in diseased
rather than healthy lungs before translating these observations
into a therapeutic approach.
Conclusions. The results of the present studies support the use
of the pulmonary route to administer capreomycin for TB or
MDR TB treatment, since a systemic disposition similar to that of
i.m. administration can be obtained with the advantage of achiev-
ing significantly higher drug concentrations in the lung environ-
ment. The fact that these concentrations are sustained above the
MIC implies that the drug may be still available in the lung for
prolonged periods of time to act on local Mycobacterium tubercu-
losis even after systemic concentrations are below the MIC. Thus,
it may be possible to use a smaller dose of capreomycin by inha-
lation and limit its systemic toxicity. Further studies are required
to address the efficacy of such a dosing regimen and its safety in
humans.
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